Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

Body mass index and heart failure risk: a cohort study in 1.5 million individuals and Mendelian randomisation analysis

“…A recent meta-analysis of the effects of anti-glycaemic therapies on HF risk in patients with diabetes found evidence that weight change was an important effect modifier, consistent with a causal role for excess adiposity. 33 Taken together, these findings support a causal role for excess adiposity and suggest that, in line with current treatment guidelines for weight loss interventions to All rights reserved. No reuse allowed without permission.…”

Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel

“…The DECLARE study has shown that the SGLT‐2i dapagliflozin protected patients from a composite of death from CVD or hospitalization for heart failure regardless of their baseline CVD history. In addition, there is strong evidence that SGLT‐2is reduce the rates of hospitalization for heart failure in patients without a history of heart failure or CVD 44 and that they also provide protection from hard renal events, even in patients with normal kidney function at baseline 48 …”

Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl

“…In ASCVD patients with <4% risk of an ASCVD event per year and an LDL-C <100 mg/dl on maximally tolerated statin therapy, alternatives to further LDL-C lowering are reasonable to consider as a next step. Depending on patient characteristics, costs, potential for adverse effects, and patient preferences and priorities [ 38 ], options for the next secondary prevention therapy may include icosapent ethyl in patients with triglycerides ≥150 mg/dl [ 39 ], a sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 receptor (GLP-1) agonist in patients with diabetes or heart failure [ 40 ], or rivaroxaban in patients with coronary or peripheral artery disease at low bleeding risk [ 41 , 42 ].…”